05.02.2014:
Tiltan Pharma Raises $1.5 Million.
The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer.
Read more...
13.11.2012:
Tiltan Pharma Announces Enrollment of First U.S. Patient
In A Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment For Metastatic Pancreatic Cancer.
Read more...
30.10.2012:
YISSUM BIOTECH HOLDING CO INTEGRA RAISES $7M
TO BE INVESTED IN YISSUM HOLDING COMPANIES INCLUDING TILTAN PHARMA.
Globes.
Read more...
17.07.2012:
Tiltan Pharma Receives FDA Approval
To Conducts Its Phase 2 Clinical Study Of Anti-Angiogenic Treatment For Pancreatic Cancer In The US.
Globes.
Read more...
13.02.2012:
Tiltan Pharma Commences Phase 2 Clinical Study
of Anti-Angiogenic Treatment for Pancreatic Cancer.
News1.
Read more...
22.06.2011:
YISSUM ANNOUNCES TILTAN PHARMA TO BE ONE OF THE LEADING PORTFOLIO COMPANIES OF ITS NEW HOLDING COMPANY INTEGRA HOLDINGS.
Globes.
Read more...
21.12.2010:
FDA Approves Tiltan’s Investigational New Drug (IND) Clinical Trial Program.
Read more...
26.04.2007:
Tiltan Has Developed An Anti-Cancer Platform That Attacks The Cancer's Supply Line Instead of The Growth Itself.
Globes.
Read more...